Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ANVS
- Price
- 2.43
- Stock movement up
- +0.39 (19.12%)
- Company name
- Annovis Bio Inc
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 33.53M
- Ent value
- 7.32B
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 107.38%
- 1 year return
- -65.68%
- 3 year return
- -35.72%
- 5 year return
- -11.83%
- 10 year return
- -
Last updated: 2025-05-29
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ANVS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 13.80M |
| EPS (TTM) | -976.17 |
| FCF per share (TTM) | -1049.54 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -30.40M |
| Net income (TTM) | -12.67B |
| EPS (TTM) | -976.17 |
| EPS (1y forward) | -0.87 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 12.64M |
| Net receivables | 0.00 |
| Total current assets | 14.36M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 14.36M |
| Accounts payable | 4.10M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 5.39M |
| Total liabilities | 7.30B |
| Shareholder's equity | -7.28B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -13.62B |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -13.62B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -88198.24% |
| Return on Invested Capital | 173.91% |
| Cash Return on Invested Capital | 186.98% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.11 |
| Daily high | 2.58 |
| Daily low | 2.04 |
| Daily Volume | 1.43M |
| All-time high | 120.97 |
| 1y analyst estimate | 34.80 |
| Beta | 1.70 |
| EPS (TTM) | -976.17 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 Aug 2025 |
Downside potential
Loading...
Downside potential data
| ANVS | S&P500 | |
| Current price drop from All-time high | -97.99% | -4.11% |
| Highest price drop | -98.99% | -56.47% |
| Date of highest drop | 17 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -71.46% | -11.06% |
| Avg time to new high | 34 days | 12 days |
| Max time to new high | 974 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
33.53M
Marketcap category
Small-cap
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Employees
6
Website
Investor relations
-
SEC filings
CEO
Maria-Luisa Maccecchini
Country
USA
City
Berwyn
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page